Empagliflozin as Add-on to Linagliptin and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Region in a 24-Week Randomized Trial

被引：0
|
作者：
Wanner, Christoph
Naderali, Ebrahim
Maldonaldo, Mario
Del Parigi, Angelo
Toorawa, Robert
Lee, Christopher
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106-P
引用
收藏
页码：A288 / A289
页数：2
相关论文
共 50 条
  • [1] Empagliflozin as Add-on to Linagliptin and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Baseline Demographics in a 24-Week Randomized Trial
    Seufert, Jochen
    Naderali, Ebrahim
    Maldonaldo, Mario
    Del Parigi, Angelo
    Toorawa, Robert
    Lee, Christopher
    [J]. DIABETES, 2016, 65 : A292 - A292
  • [2] Empagliflozin (EMPA) as add-on to linagliptin (LINA) and metformin in patients with type 2 diabetes (T2DM): a 24-week randomised, double-blind, parallel-group trial
    Maldonado-Lutomirsky, M.
    Softeland, E.
    Meier, J. J.
    Vangen, B.
    Toorawa, R.
    Woerle, H. -J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2016, 59 : S93 - S93
  • [3] Linagliptin (LINA) as Add-on to Empagliflozin (EMPA) and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Baseline Demographics in Two 24-Week Randomized, Double-Blind, Parallel-Group Trials
    Kis, Sanja Giljanovic
    Khunti, Kamlesh
    Maldonaldo, Mario
    Del Parigi, Angelo
    Goetz, Sophia
    Lee, Christopher
    [J]. DIABETES, 2016, 65 : A297 - A298
  • [4] Empagliflozin (EMPA) as Add-on to Linagliptin (LINA) and Metformin in Patients with Type 2 Diabetes (T2DM): A 24-Week Randomized, Double-Blind, Double-Dummy, Parallel-Group Trial
    Softeland, Eirik
    Meier, Juris J.
    Vangen, Bente
    Toorawa, Robert
    Maldonado, Mario
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2016, 65 : A295 - A295
  • [5] Linagliptin (LINA) as add-on to empagliflozin (EMPA) and metformin in patients with type 2 diabetes (T2DM): two 24-week randomised, double-blind, parallel-group trials
    Tinahones, F. J.
    Gallwitz, B.
    Nordaby, M.
    Goetz, S.
    Maldonado-Lutomirsky, M.
    Woerle, H. -J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2016, 59 : S371 - S372
  • [6] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES, 2013, 62 : A282 - A282
  • [7] Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
    Softeland, Eirik
    Meier, Juris J.
    Vangen, Bente
    Toorawa, Robert
    Maldonado-Lutomirsky, Mario
    Broedl, Uli C.
    [J]. DIABETES CARE, 2017, 40 (02) : 201 - 209
  • [8] Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES CARE, 2014, 37 (06) : 1650 - 1659
  • [9] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [10] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A278 - A278
12345